Know Cancer

or
forgot password

The Impact of Pediatric Marrow Transplantation on Late Pulmonary Function


N/A
N/A
17 Years
Not Enrolling
Both
Long-term Effects Secondary to Cancer Therapy in Children, Pulmonary Complications

Thank you

Trial Information

The Impact of Pediatric Marrow Transplantation on Late Pulmonary Function


OBJECTIVES:

- Determine the delayed effects of bone marrow transplantation preparative regimens on
pulmonary function in children surviving at least 5 years after transplantation for
hematologic malignancy.

- Determine the relationship between pulmonary function and growth rates in these
patients.

- Determine the effect of growth hormone treatment on pulmonary function in these
patients.

- Determine the relationship between pulmonary function and age at time of
transplantation in these patients.

- Determine the incidence and severity of restrictive pulmonary disease, and whether
these factors vary with increasing time after transplantation in these patients.

OUTLINE: Patients undergo respiratory history, signs and symptoms assessment, pulmonary
function tests (PFT) including spirometry, lung volumes, and diffusion, oxygen saturation by
pulse oximetry, and height measurement.

Patients are assessed at 5-10 years, 10-15 years, and over 15 years after bone marrow
transplantation. Patients with abnormal PFTs are assessed at more frequent intervals as
clinically indicated.

PROJECTED ACCRUAL: Approximately 280 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Patients who have undergone bone marrow transplantation for hematologic malignancy at
least 5 years ago

- Disease-free survivors at least 6 years of age AND

- Under 18 years of age at time of transplantation

- Received prior allogeneic, unrelated donor, syngeneic, or autologous bone marrow
transplantation

- Able to perform pulmonary function tests

PATIENT CHARACTERISTICS:

Age:

- See Disease Characteristics

Performance status:

- Not specified

Life expectancy:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- Not specified

Renal:

- Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- See Disease Characteristics

Chemotherapy:

- Not specified

Endocrine therapy:

- Not specified

Radiotherapy:

- Not specified

Surgery:

- Not specified

Other:

- Any prior preparative regimen allowed

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

Jean E. Sanders, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Fred Hutchinson Cancer Research Center

Authority:

United States: Federal Government

Study ID:

1097.00

NCT ID:

NCT00009711

Start Date:

March 1996

Completion Date:

August 2005

Related Keywords:

  • Long-term Effects Secondary to Cancer Therapy in Children
  • Pulmonary Complications
  • long-term effects secondary to cancer therapy in children
  • pulmonary complications

Name

Location

Fred Hutchinson Cancer Research CenterSeattle, Washington  98109